The seven-year preliminary results of Brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center

International Braz J Urol

Volumn 33, Issue 6, 2007, Pages 752-763

  Franca, Carlos Antônio da Silva ^a,b   Vieira, Sergio L ^a   Bernabe, Antonio J S ^a   Penna, Antonio B R ^a  

^a Brazilian Institute of Osteopathy (IBO)   (Brazil)

^b NONE   (Brazil)

Author keywords

Brachytherapy; Iodine radioisotopes; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

EID: 38849168908     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382007000600003     Document Type: Article

References (31)

1. INCA. Estimativa 2006: Incidência de câncer no Brasil. Rio de Janeiro. 2005; p. 34. http://www.inca.gov.br/estimativa/2006/ versaofinal.pdf.
2. Jani AB, Feinstein JM, Pasciak R, Krengel S, Weichselbaum RR: Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. Urology, 2006; 67: 1007-11.
3. Potters L, Morgenstern C, Calugam E, Fearn P, Jassal A, Presser J, et al.: 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005; 173: 1562-6.
4. Menick GS, Butler WM, Galbreath RW, Lief JH: Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001; 51:41-8.
5. Blasko JC, Ragde H, Grimm PD, Cavanagh W: Prostate brachytherapy: importance of technique. J Clin Oncol. 1996; 14: 1965-7.
6. a Ed. MEDSI, 1999; pp. 671-4.
7. Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H: A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma, of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006; 64: 804-9.
8. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Stonne G, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
9. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al.: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-90.
10. Stock RG, Cesaretti JA, Stone NN: Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 64: 810-6.
11. TNM: Classificação de tumores malignos. (6 ed.), Rio de Janeiro, INCA. 2004; pp. 190-3.
12. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA: Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys. 2003; 57: 944-52.
13. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS: Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 American Association of Physicists in Medicine.Med Phys. 1995; 22: 209-34. Erratum in: Med Phys 1996; 23: 1579.
14. No authors listed: Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997; 37: 1035-41.
15. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, et al.: Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005; 61: 1019-34.
16. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W: Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839-50.
17. Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS: Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 2000; 89: 135-41.
18. Critz EA, Williams WH, Levinson AK, Benton JB, Holladay CT, Schnell FJ Jr: Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol. 2000; 164: 738-41; discussion 741-3.
19. Izard MA, Haddad RL, Fogarity GB, Rinks A, Dobbins T, Katelaris P: Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci 192Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66: 38-47.
20. Kwok Y, DiBiase SJ, Amin PP, Naslund M, Sklar G, Jacobs SC: Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys. 2002; 53: 588-94.
21. Guedea F, Aguilo F, Polo A, Langley S, Laing R, Henderson A, et al.: Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. Radiother Oncol. 2006; 80: 57-61.
22. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK: A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998; 41: 101-8.
23. Febles C, Valicenti RK: Combining external beam radiotherapy with prostate brachytherapy: issues and rationale. Urology. 2004; 64: 855-61.
24. Singh A, Zelefsky MJ, Raben A, Lombardi D, Leibel SA: Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Cancer. 2000; 90: 275-80.
25. Zapatero A, Alcantara P, Valcarcel F, de la Torre A, Calvo FA, Algas R, et al.: Preliminary Report of a Multicenter Spanish Trial (GICOR 05) Of Risk-Adapted Androgen Ablation Combined With Dose-Escalation 3D Conformal Therapy For Prostate Cancer: Impact On Early Toxicity. Int J Radiat Oncol Biol Phys. 2003; 57 (Suppl 2): S391-2.
26. Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, et al.: RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys. 2003; 57: 614-20.
27. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S: Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999; 45: 59-67.
28. Gelblum DY, Potters L: Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 48: 119-24.
29. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-74.
30. Pan CC, Bae K, Hanks GE, Shipley WU, Roach M, Sandler HM. Comparison of Two Types of Biochemical Failures Within the ASTRO and Phoenix Consensus Definitions in Patients Treated on RTOG 92-02 and 94-13. Int J Radiat Oncol Biol Phys. 2006; 66 (Suppl 3): S318.
31. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, et al.: Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006; 65: 1487-93.